Eli Lilly and Company– tag –
-
Global and Korean Pharma Intensify Race for Next-Gen Oral Obesity Drugs: GLP-1/GIP Dual Agonists and Microneedle Patches Emerge
Chosun Biz South Korea Overview The 2026 European Congress on Obesity highlighted intensified global competition in next-generation oral obesity drug development. Viking Therapeutics announced positive Phase 2 results for its oral GLP-1/... -
Isomorphic Labs Secures $2.1 Billion for AI Drug Discovery, Scaling AlphaFold-Driven Platform for Diverse Modalities
Pharmaceutical Technology UK Overview Isomorphic Labs, an Alphabet-backed AI drug discovery company, has closed a monumental $2.1 billion Series B funding round to accelerate its AI-driven drug development efforts. The investment will pr...
